Muscarinic receptor antagonist. Prepn: N. A. Jnsson et al., EP 325571 (1989 to KabiVitrum); eidem, US 5382600 (1995 to Pharmacia). Asymmetric total synthesis: C. Hedberg, P. G. Andersson, Adv. Synth. Catal. 347, 662 (2005). Pharmacology: L. Nilvebrant et al., Life Sci. 60, 1129 (1997). Receptor binding study: idem et al., Eur. J. Pharmacol. 327, 195 (1997). GC-MS determn in biological fluids: L. Palmér et al., J. Pharm. Biomed. Anal. 16, 155 (1997). Clinical pharmacokinetics: N. Brynne et al., Int. J. Clin. Pharmacol. Ther. 35, 287 (1997). Review of clinical trials: R. A. Appell, Urology 50, Suppl. 6A, 90-96 (1997); of use in overactive bladder: E. S. Rovner, Expert Opin. Pharmacother. 6, 653-666 (2005).
In treatment of urinary incontinence.
Antimuscarinic